Series C Funded Biotechnology Startups
The largest disclosed Series C in this biotechnology set is NewLimit’s $435M round (2026-06-02), which dwarfs the next-largest disclosed amount of $358M (T…
The largest disclosed Series C in this biotechnology set is NewLimit’s $435M round (2026-06-02), which dwarfs the next-largest disclosed amount of $358M (Tubulis, 2025-10-19) and sits well above the rest of the disclosed top cluster. Amounts also show clustering: multiple high-to-mid eight-figure rounds appear across a short window in 2025–2026, with Science at $230M (2026-03-05) and Triveni Bio at $65M (2026-06-17) alongside several Cambridge-based companies (8 entries total) and a smaller concentration in San Francisco (3) and Boston (3). A clear outlier on the low end is ENYO Pharma’s $7M (2025-06-12), while two entries remain undisclosed (Click Therapeutics on 2025-03-19 and Cortechs.ai on 2024-11-20), which can mask true dispersion. Temporally, rounds span from 2024-07-16 to 2026-07-16, with the most recent disclosed close being Trellis Bioscience’s $9M on 2026-07-16.
Most recent rounds
50 of 179129 more funded startups
This page shows the 50 most recent rounds (back to Jul 2024). The full 179-company history for this listing is available on a paid plan.
Unlock all 179 companies in this listing — full funding history, investors, and founders.
Related listings
Frequently asked
How does the largest disclosed Series C compare to the rest of the disclosed amounts?
NewLimit’s $435M (2026-06-02) is the only disclosed round above the $300M range and sits far above the next-largest disclosed amount of $358M (Tubulis, 2025-10-19). The top disclosed tier then steps down to $325M (ArsenalBio, 2024-09-04) and $313M (Kriya Therapeutics, 2025-08-15).
Are there identifiable city concentrations among these Series C biotechnology rounds?
Cambridge is over-represented with 8 entries, including Flare Therapeutics ($85M on 2026-06-30), Storm Therapeutics (2026-04-16, $56M), and Cognito Therapeutics ($105M on 2026-03-05). San Francisco (3 entries) and Boston (3 entries) appear more frequently than other single-city locations, but at a smaller scale than Cambridge.
Which deals closed in the most recent 90 days of the list?
Using the latest round date shown (2026-07-16), the 90-day window covers 2026-04-17 through 2026-07-16. Within that range, disclosed rounds include Trellis Bioscience ($9M, 2026-07-16), Wugen ($35M, 2026-07-08), Flare Therapeutics ($85M, 2026-06-30), and Terremoto Biosciences ($108M, 2026-04-15 is just outside the window, so excluded).
Do undisclosed amounts create blind spots in the apparent funding-size distribution?
Two of 50 entries are undisclosed—Click Therapeutics on 2025-03-19 and Cortechs.ai on 2024-11-20—so any analysis that relies only on disclosed amounts will omit potentially material outliers. The disclosed smallest amount is ENYO Pharma’s $7M on 2025-06-12, providing a lower bound for visible dispersion.
Are there notable high- and low-end outliers worth flagging for diligence?
On the high end, the list shows a sharp concentration at the top: NewLimit ($435M, 2026-06-02), Tubulis ($358M, 2025-10-19), and ArsenalBio ($325M, 2024-09-04). On the low end, ENYO Pharma’s $7M (2025-06-12) contrasts with multiple other mid-size rounds such as Triveni Bio ($65M, 2026-06-17) and MBX Biosciences ($64M, 2024-08-05).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.